References
- Bassiri RM, Utiger RD. (1973). Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans. J Clin Invest 52:1616–9.
- Bruderer S, Hopfgartner G, Seiberling M. (2012). Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 42:901–10.
- Daimon CM, Chirdon P, Maudsley S, Martin B. (2013). The role of thyrotropin releasing hormone in aging and neurodegenerative diseases. Am J Alzheimers Dis 1. doi: 10.7726/ajad.2013.1003
- European medicines agency (EMA). Guideline on the investigation of drug interactions, June 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf [last accessed 19 Feb 2019].
- Griffiths EC. (1976). Peptidase inactivation of hypothalamic releasing hormones. Horm Res 7:179–91.
- Guillemin R. (1978). Peptides in the brain: the new endocrinology of the neuron. Science 202:390–402.
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13.
- Ijiro T, Nakamura K, Ogata M, et al. (2015). Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system. Eur J Pharmacol 761:413–22.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). (2009). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, M3(R2), 5, Geneva, Switzerland.
- Isin EM, Elmore CS, Nilsson GN, et al. (2012). Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies. Chem Res Toxicol 25:532–42.
- Khomane KS, Meena CL, Jain R, Bansal AK. (2011). Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin Ther Pat 21:1673–91.
- Kinoshita K, Yamamura M, Sugihara J, et al. (1998). Taltirelin hydrate (TA-0910): an orally active thyrotropin-releasing hormone mimetic agent with multiple actions. CNS Drug Rev 4:25–41.
- Kobayashi K, Abe Y, Harada H, et al. (2019). Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue. Xenobiotica 49:106–19.
- Marchitti SA, Brocker C, Stagos D, Vasiliou V. (2008). Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4:697–720.
- Ministry of Health, Labour and Welfare (MHLW), Drug interaction guideline for drug development and labeling recommendations, July 2018. https://www.pmda.go.jp/files/000225191.pdf [last accessed 19 Feb 2019].
- Morley JE. (1979). Extrahypothalamic thyrotropin releasing hormone (TRH) - its distribution and its functions. Life Sci 25:1539–50.
- Nijenhuis CM, Schellens JH, Beijnen JH. (2016). Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metab Rev 48:266–80.
- Penner N, Klunk LJ, Prakash C. (2009). Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185–203.
- Penner N, Xu L, Prakash C. (2012). Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513–31.
- Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43.
- Schally AV. (1978). Aspects of hypothalamic regulation of the pituitary gland. Science 202:18–28.
- Sidhu RS, Blair AH. (1975). Human liver aldehyde dehydrogenase. Esterase activity. J Biol Chem 250:7894–8.
- Shimizu Y, Yamano H, Kiyono Y, Ijiro T. (2018). Administration regimen for therapeutic agents for ataxia in spinocerebellar degeneration. United States Patent Application Publication. Publication number: US 2018/0147189 A1. Publicatiion Date: May 31, 2018.
- Sobue I, Takayanagi T, Nakanishi T, et al. (1983). Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci 61:235–48.
- U.S. Food and Drug Administration (FDA). In vitro metabolism- and transporter- mediated drug-drug interaction studies guidance for industry (draft), October 2017. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM581965.pdf [last accessed 19 Feb 2019].
- Walker D, Brady J, Dalvie D, et al. (2009). A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 22:1653–62.
- Yamada M, Monden T, Konaka S, Mori M. (1993). Assignment of human thyrotropin-releasing hormone (TRH) receptor gene to chromosome 8. Somat Cell Mol Genet 19:577–80.
- Yoshida A, Rzhetsky A, Hsu LC, Chang C. (1998). Human aldehyde dehydrogenase gene family. Eur J Biochem 251:549–57.